Preclinical research often hypes cancer drugs

Researchers at McGill say that the preclinical research field is badly skewed, favoring the publication of positive results in a way that has helped inspire more poorly designed studies for new therapies--studies which often can't be reproduced later. And they used Sutent (sunitinib) as a case study. "Only a fraction of drugs that show promise in animals end up proving safe and effective in humans," says lead researcher Dr. Jonathan Kimmelman, who directs the STREAM (Studies in Translation, Ethics and Medicine) research group. "An important reason is because studies in animals are often not well designed, and because positive results have a higher chance of being published. They end up skewing what we think we know about the potential of a drug." Release

Suggested Articles

Scientists used machine learning and CRISPR-Cas9 to control the patterns iPSCs form in lab dishes, an important step to create functional organs.

Combining AZ's MCL1 inhibitor AZD5991 with existing MEK or BRAF inhibitors could kill melanoma cells more effectively, scientists found.

Combining a checkpoint inhibitor with an anti-TFG-beta drug was effective in mouse models of metastatic prostate cancer, MD Anderson researchers said.